The Establishing of A New  Hemodynamic Paradigm 

                          E Ppour Si Muove

                    (And yet it moves!! Galileo Galilei)


You might remember, from reading earlier, that when LUGEVI-II was first exposed to the scientific community specializing in this kind of evaluation, their opinion was not favorable. They argued that LUGEVI's functioning contradicted certain hemodynamic grounding principles, and they contended, additionally, that such control as provided by this device would be useless because it would not reach levels that could be considered therapeutically useful.


As has happened so many times in scientific life, however, a grain of facts overthrows a ton of theory. After we observed the Noradrenaline metabolism time for both dogs and truly determined its effect, we proceeded to test if the bionic emulator device could really catch a hypertension surge. It certainly did. In the first case, without the device installed, the hypertension surge reached a peak of 225/117 mmHg after 10 minutes, returning to a normal 94/44 mmHg after 5 minutes; whereas, with the device installed, blood pressure reached a peak of 137/62 mmHg after 4 minutes, returning to normal 98/47 mmHg after 3 minutes.


Why is this so important? If in a real setting this patient had had a HBP surge without having the emulator device installed, he/she could have had a stroke or a heart attack. Arterial hypertension is the most important risk factor for both ischemia and cerebral hemorrhage, and is found in almost 70% of stroke patients.


Let’s closely examine the blood pressure figures of our second patient. As we had with the first patient, we tested the effect of Noradrenaline metabolism: it produced a Median BP of 271 mmHg after 5 minutes, returning to a Median BP of 81 mmHg after 25 minutes. During the second event, with our device installed, the device immediately activated after the HBP surge of 204 mmHg, and it began to consistently lower the BP to 110 mmHg over 10 minutes, returning to 77 mmHg after 15 minutes.


What do these figures mean? Nothing short of a new breakthrough for hypertension treatment, and the clear possibility to prevent TOTALLY RANDOM, SUDDEN SURGES OF HYPERTENSION, a breakthrough which consequently opens the gate for the prevention of 


In any case, none of the dogs died as a result of the experiments. They were treated with care and concern, and the Veterinary Hospital adhered to all internationally standard ethical practices and procedures.

If we define hypertension as a generalized vasoconstriction of the whole arterial system, we will see that such a condition, regardless of how it is counter-attacked by the whole human body, is duly commanded by the brain in a major effort to expand the arterial vessels in trying to bring body’s set points to the right function, that is, to increase the Compliance of the system.


But Compliance diminishes as we grow older, so the only solution is to have a system capable of waiting for that to happen. Now, the only question is: do we have that time?  A long time will pass before blood pressure begins to descend on its own. In other words, LUGEVI-II, by design, will get there first!
















In the beginning of our tests, we used pigs, as is customary. However, pigs are extremely nervous and susceptible  to stress, hard to handle, prone to hyperthermia, and have short legs, complicating access to the femoral artery. We thus decided to switch to dogs; the only problem we had with them was their extreme resistance to hypertension.